# Title
Interactions O
of O
human B-Species
P-glycoprotein B-Gene
with O
simvastatin, B-Chemical
simvastatin B-Chemical
acid, I-Chemical
and O
atorvastatin. B-Chemical

# Abstract
PURPOSE: O
In O
this O
study, O
P-glycoprotein B-Gene
(P-gp) B-Gene
mediated O
efflux O
of O
simvastatin B-Chemical
(SV), B-Chemical
simvastatin B-Chemical
acid I-Chemical
(SVA), B-Chemical
and O
atorvastatin B-Chemical
(AVA) B-Chemical
and O
inhibition O
of O
P-gp B-Gene
by O
SV, B-Chemical
SVA, B-Chemical
and O
AVA B-Chemical
were O
evaluated O
to O
assess O
the O
role O
of O
P-gp B-Gene
in O
drug O
interactions. O
METHODS: O
P-gp B-Gene
mediated O
efflux O
of O
SV, B-Chemical
SVA, B-Chemical
and O
AVA B-Chemical
was O
determined O
by O
directional O
transport O
across O
monolayers O
of O
LLC-PK1 B-CellLine
cells O
and O
LLC-PK1 B-CellLine
cells O
transfected O
with O
human B-Species
MDR1. B-Gene
Inhibition O
of O
P-gp B-Gene
was O
evaluated O
by O
studying O
the O
vinblastine B-Chemical
efflux O
in O
Caco-2 B-CellLine
cells O
and O
in O
P-gp B-Gene
overexpressing O
KBV1 B-CellLine
cells O
at O
concentrations O
of O
SV, B-Chemical
SVA, B-Chemical
and O
AVA B-Chemical
up O
to O
50 O
microM. O
RESULTS: O
Directional O
transport O
studies O
showed O
insignificant O
P-gp B-Gene
mediated O
efflux O
of O
SV, B-Chemical
and O
moderate O
P-gp B-Gene
transport O
[2.4-3.8 O
and O
3.0-6.4 O
higher O
Basolateral O
(B) O
to O
Apical O
(A) O
than O
A O
to O
B O
transport] O
for O
SVA B-Chemical
and O
AVA, B-Chemical
respectively. O
Inhibition O
studies O
did O
not O
show O
the O
same O
trend O
as O
the O
transport O
studies O
with O
SV B-Chemical
and O
AVA B-Chemical
inhibiting O
P-gp B-Gene
(IC50 O
-25-50 O
microM) O
but O
SVA B-Chemical
not O
showing O
any O
inhibition O
of O
P-gp. B-Gene
CONCLUSIONS: O
The O
moderate O
level O
of O
P-gp B-Gene
mediated O
transport O
and O
low O
affinity O
of O
SV, B-Chemical
SVA, B-Chemical
and O
AVA B-Chemical
for O
P-gp B-Gene
inhibition O
compared O
to O
systemic O
drug O
levels O
suggest O
that O
drug O
interactions O
due O
to O
competition O
for O
P-gp B-Gene
transport O
is O
unlikely O
to O
be O
a O
significant O
factor O
in O
adverse O
drug O
interactions. O
Moreover, O
the O
inconsistencies O
between O
P-gp B-Gene
inhibition O
studies O
and O
P-gp B-Gene
transport O
of O
SV, B-Chemical
SVA, B-Chemical
and O
AVA B-Chemical
indicate O
that O
the O
inhibition O
studies O
are O
not O
a O
valid O
means O
to O
identify O
statins O
as O
Pgp B-Gene
substrates. O